24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
EpiPen
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
14:14
Full list of Israeli high-tech funding rounds in 2025
14:11
ForSight Robotics raises $125M Series B to advance AI-powered eye surgery system
12:14
Israel expands cyber powers amid rising threats—via WhatsApp
11:51
Joonko to pay $500,000 to ex-CEO Ilit Raz as part of court-approved settlement
More stories
Buzz
Most popular
Daily
Weekly
1
Microsoft gives Israeli employees time off, while Mobileye and others rush to aid displaced workers
2
Ilya Sutskever rejected Meta’s bid for his $32B startup, so Zuckerberg is hiring his CEO instead
3
Vibe coding fever: Solo entrepreneur’s Base44 acquired by Wix for $80 million
4
Travel-tech unicorn Navan files for IPO in rebounding market
5
Weizmann Institute suffers over $500 million in damage from missile strike
More news
EpiPen
4 stories about EpiPen
Teva Jumps on NYSE on a Bit of Good News
21.08.19
|
Hezi Sternlicht
An opioid-abuse lawsuit settlement reached by drugmakers Endo and Allergan Tuesday could bode well for Teva’s legal future, as does the release of an FDA-approved generic version of EpiPen JR
Teva, Mylan Drop on Announcement of Epinephrine Injector Rival
09.12.18
|
Lilach Baumer
Novartis’ U.S. division Sandoz announced a planned release for early 2019. The company will sell its drug, which lacks the EpiPen’s auto-injector, for $250 a pair out of pocket, compared to Mylan and Teva’s $300
Teva’s Generic EpiPen Now Available in the U.S. in Limited Numbers
28.11.18
|
Lilach Baumer
In August, the Israel-headquartered drugmaker won approval to market the first generic EpiPen auto-injectors in the U.S.
Teva’s EpiPen Won’t Hit U.S. Market in Time for School Year, Report Says
26.08.18
|
Dror Reich
The Israeli drugmaker received approval for a first generic version of Mylan’s auto-injector earlier this month